June 14, 2018
Sunovion Pharmaceuticals, a US subsidiary of Sumitomo Dainippon Pharma, said on June 12 that the US FDA has accepted its new drug application (NDA) for the Parkinson’s disease treatment APL-130277. The agent is a sublingual film formulation of apomorphine designed...read more